Key Details
Price
$0.00Annual ROE
119.72%Beta
-0.40Events Calendar
Next earnings date:
Feb 12, 2025Recent quarterly earnings:
Feb 12, 2024Recent annual earnings:
Jun 30, 2020Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 5, 2019Analyst ratings
Recent major analysts updates
Aug 21, 23 HC Wainwright & Co.
BuyJul 17, 23 EF Hutton
BuyMar 30, 23 EF Hutton
BuyFeb 28, 23 EF Hutton
BuyFeb 27, 23 HC Wainwright & Co.
BuyAug 19, 22 HC Wainwright & Co.
BuyMar 29, 22 HC Wainwright & Co.
BuyDec 2, 21 EF Hutton
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Price
Market cap
Technical
Dividend
Nemaura Medical doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Leverage
Risk & Stability
Balance Sheet
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Assets
Equity
Liabilities
Debt
Expenses
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
NMRD
GlobeNewsWireSeptember 18, 2023
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present business updates and developments at the Maxim Group Emerging Growth in A.I., virtual conference.
Nemaura Medical, Inc. (NMRD) Upgraded to Buy: What Does It Mean for the Stock?
NMRD
Zacks Investment ResearchAugust 23, 2023
Nemaura Medical, Inc. (NMRD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FAQ
- What is the ticker symbol for Nemaura Medical?
- Does Nemaura Medical pay dividends?
- What sector is Nemaura Medical in?
- What industry is Nemaura Medical in?
- What country is Nemaura Medical based in?
- When did Nemaura Medical go public?
- Is Nemaura Medical in the S&P 500?
- Is Nemaura Medical in the NASDAQ 100?
- Is Nemaura Medical in the Dow Jones?
- When was Nemaura Medical's last earnings report?
- When does Nemaura Medical report earnings?
- Should I buy Nemaura Medical stock now?
What is the ticker symbol for Nemaura Medical?
The ticker symbol for Nemaura Medical is NASDAQ:NMRD
Does Nemaura Medical pay dividends?
No, Nemaura Medical does not pay dividends
What sector is Nemaura Medical in?
Nemaura Medical is in the Healthcare sector
What industry is Nemaura Medical in?
Nemaura Medical is in the Medical Devices industry
What country is Nemaura Medical based in?
Nemaura Medical is headquartered in United States
When did Nemaura Medical go public?
Nemaura Medical's initial public offering (IPO) was on February 5, 2018
Is Nemaura Medical in the S&P 500?
No, Nemaura Medical is not included in the S&P 500 index
Is Nemaura Medical in the NASDAQ 100?
No, Nemaura Medical is not included in the NASDAQ 100 index
Is Nemaura Medical in the Dow Jones?
No, Nemaura Medical is not included in the Dow Jones index
When was Nemaura Medical's last earnings report?
Nemaura Medical's most recent earnings report was on Feb 12, 2024
When does Nemaura Medical report earnings?
The next expected earnings date for Nemaura Medical is Feb 12, 2025
Should I buy Nemaura Medical stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions